.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

TAMIFLU Drug Profile

« Back to Dashboard
Tamiflu is a drug marketed by Roche and is included in two NDAs. It is available from six suppliers. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has fifty-seven patent family members in twenty-eight countries.

The generic ingredient in TAMIFLU is oseltamivir phosphate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

Summary for Tradename: TAMIFLU

Patents:3
Applicants:1
NDAs:2
Suppliers / Packagers: see list6
Drug Prices: :see details

Pharmacology for Tradename: TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-002Mar 21, 2011RXYes5,763,483*PED► subscribeY► subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-001Oct 27, 1999RXYes5,866,601*PED► subscribeY► subscribe
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-001Dec 14, 2000DISCNNo5,952,375*PED► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-001Dec 14, 20005,952,375*PED► subscribe
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-001Dec 14, 20005,866,601*PED► subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-001Oct 27, 19995,866,601*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TAMIFLU

Drugname Dosage Strength RLD Submissiondate
oseltamivir phosphateOral Suspension6 mg/mLTamiflu6/18/2015
oseltamivir phosphateCapsules30 mg and 45 mgTamiflu8/2/2011
oseltamivir phosphateCapsule75 mgTamiflu11/15/2010

Non-Orange Book Patents for Tradename: TAMIFLU

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,225,341 Compounds and methods for synthesis and therapy► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TAMIFLU

Country Document Number Estimated Expiration
China1733707► subscribe
Hong Kong1088594► subscribe
Japan3300365► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TAMIFLU

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2002 00027Denmark► subscribe
991Luxembourg► subscribe
C031/2002Ireland► subscribeSPC031/2002: 20021107, EXPIRES: 20160226
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc